{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:ema:tarceva:0:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Atarceva%3A0%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002047,
    "timestamp_received": "2026-10-16T22:57:45.308918+00:00Z",
    "timestamp_returned": "2026-10-16T22:57:45.310965+00:00Z",
    "trace_id": "b65bae17-8791-4136-8e59-e4a3d0b5d8df"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:ema:tarceva:0:0",
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2011-08-24:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2011-08-24",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:tarceva",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tarceva (erlotinib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Roche Registration GmbH.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tarceva",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "erlotinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2009-07-14",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-05-16",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:669",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C2926",
          "conceptType": "Disease",
          "name": "Non-Small Cell Lung Cancer",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:NSCLC",
                "code": "NSCLC",
                "name": "Non-Small Cell Lung Cancer",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Non-Small+Cell+Lung+Cancer+%28NSCLC%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C2926",
            "code": "C2926",
            "name": "Lung Non-Small Cell Carcinoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2926"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C65530",
          "conceptType": "Therapy",
          "name": "Erlotinib",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:337525",
                "code": "337525",
                "name": "erlotinib",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=337525"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:1325363",
                "code": "1325363",
                "name": "erlotinib",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1325363"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "EGFR inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C65530",
            "code": "C65530",
            "name": "Erlotinib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:19",
                "present": true,
                "subject": {
                  "id": "bmkr:19",
                  "type": "CategoricalVariant",
                  "name": "EGFR activating variants",
                  "constraints": [
                    {
                      "type": "DefiningLocationConstraint",
                      "location": {
                        "id": "ga4gh:SL.gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt",
                        "type": "SequenceLocation",
                        "name": null,
                        "aliases": [],
                        "description": "Sequence spanning the length of refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).",
                        "digest": "gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt",
                        "sequenceReference": {
                          "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                          "type": "SequenceReference",
                          "name": "NP_005219.2",
                          "aliases": [
                            "ensembl:ENSP00000275493.2",
                            "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                            "refseq:NP_005219.2"
                          ],
                          "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.",
                          "moleculeType": "protein",
                          "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                          "residueAlphabet": "aa"
                        },
                        "start": 0,
                        "end": 1210,
                        "sequence": null
                      },
                      "relations": [],
                      "matchCharacteristic": {
                        "primaryCoding": {
                          "code": "is_within",
                          "system": "ga4gh-gks-term:location-match"
                        }
                      }
                    },
                    {
                      "type": "FeatureContextConstraint",
                      "featureContext": {
                        "id": "gene:hgnc:3236",
                        "conceptType": "Gene",
                        "name": "EGFR",
                        "primaryCoding": {
                          "id": "coding:hgnc:3236",
                          "code": "HGNC:3236",
                          "system": "https://genenames.org",
                          "iris": [
                            "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"
                          ]
                        },
                        "mappings": [
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ensembl:ensg00000146648",
                              "code": "ENSG00000146648",
                              "system": "https://www.ensembl.org",
                              "iris": [
                                "https://www.ensembl.org/id/ENSG00000146648"
                              ]
                            }
                          },
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ncbi:1956",
                              "code": "1956",
                              "system": "https://www.ncbi.nlm.nih.gov/gene",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/gene/1956"
                              ]
                            }
                          },
                          {
                            "relation": "relatedMatch",
                            "coding": {
                              "id": "coding:refseq:NM_005228.5",
                              "code": "NM_005228.5",
                              "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"
                              ]
                            }
                          }
                        ]
                      }
                    },
                    {
                      "type": "FunctionConstraint",
                      "functionConsequence": {
                        "id": "func:so:0002053",
                        "name": "Gain-of-function",
                        "primaryCoding": {
                          "id": "coding:so:0002053",
                          "code": "SO:0002053",
                          "name": "gain_of_function_variant",
                          "system": "https://www.ebi.ac.uk/ols4/ontologies/so",
                          "iris": [
                            "https://www.ebi.ac.uk/ols4/ontologies/so/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FSO_0002053"
                          ]
                        }
                      }
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Somatic variant"
                    },
                    {
                      "name": "chromosome",
                      "value": "7"
                    },
                    {
                      "name": "start_position",
                      "value": null
                    },
                    {
                      "name": "end_position",
                      "value": null
                    },
                    {
                      "name": "reference_allele",
                      "value": null
                    },
                    {
                      "name": "alternate_allele",
                      "value": null
                    },
                    {
                      "name": "cdna_change",
                      "value": null
                    },
                    {
                      "name": "protein_change",
                      "value": null
                    },
                    {
                      "name": "variant_annotation",
                      "value": null
                    },
                    {
                      "name": "exon",
                      "value": null
                    },
                    {
                      "name": "rsid",
                      "value": null
                    },
                    {
                      "name": "hgvsg",
                      "value": null
                    },
                    {
                      "name": "hgvsc",
                      "value": null
                    },
                    {
                      "name": "requires_oncogenic",
                      "value": true
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:ema:tarceva:0",
            "type": "Indication",
            "description": "Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-10-20:0",
                "type": "Contribution",
                "description": "Adding EMA approvals for use to database",
                "date": "2024-10-20",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:ema:2011-08-24:0",
                "type": "Contribution",
                "description": "Indication received approval from the European Commission.",
                "date": "2011-08-24",
                "contributor": {
                  "id": "agent:org:ema",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "European Medicines Agency",
                  "description": "Regulatory agency that approves medicines for use in the European Union."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:ema:tarceva",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Tarceva (erlotinib) [product information]. EMA.",
                "title": null,
                "aliases": [],
                "description": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.",
                "urls": [
                  "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf",
                  "https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:ema",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "European Medicines Agency",
                      "description": "Regulatory agency that approves medicines for use in the European Union."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Roche Registration GmbH.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Tarceva",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "erlotinib",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2009-07-14",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2023-05-16",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}